Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amaranthus retroflexus pollen, from the plant commonly known as Redroot Pigweed, is a significant source of airborne allergens that cause respiratory allergies like pollinosis in various regions, including temperate areas of Europe, the USA, and countries like Iran. The pollen contains several allergenic proteins that trigger an IgE-mediated immune response in sensitized individuals. Key identified allergens include Ama r 1 (an Ole e 1-like protein), Ama r 2 (a profilin), and Ama r 3 (a polcalcin). These proteins are responsible for the pollen's allergenic activity and also contribute to cross-reactivity with pollens from other plants in the Amaranthaceae/Chenopodiaceae family, such as Chenopodium album (lamb's quarters) and Salsola kali (Russian thistle). Extracts of Amaranthus retroflexus pollen are used commercially for the diagnosis of allergies through methods like the skin prick test (SPT) and for allergen-specific immunotherapy to desensitize patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amaranthus retroflexus pollen.